2022 AMI Online Salon
TCR β Chain-Directed Bispecific Antibodies: Treatment for T Cell Cancers
Project Details
- Entrant Name: Tina Wang
- Client: Sandra Gabelli, Fabian de Kok-Mercado
- Copyright: Tina Wang, 2021
- Medium/software used: Cinema 4D, Adobe Photoshop
- Final presentation format: Poster
- Primary Audience: Cancer researchers, immunologists
Project Description
T cell receptor (TCR), a transmembrane heterodimer expressed on both normal and malignant T cells, contains variable genes in the β chain called TRBVs. Clonally expanded malignant T cells express the same TRBV, which acts as an antigen that can be specifically targeted by engineered bispecific antibodies (BsAbs). BsAbs can be a viable off-the-shelf treatment option for T cell cancers. The purpose of this poster is to promote and educate researchers about how BsAbs help normal T cells target and kill malignant T cells.Bright colors of TCR contrasted against the desaturated cell membranes and background help draw viewer’s eyes. A combination of surface and ribbon models contrast the BsAb from the 2 TCRs it binds to. To the right, IFN exocytosis is shown as a consequence of BsAb binding. Cross-sections of normal and malignant T cell membranes are shown to put the binding into 3-dimensional context. Instructional color in both the main image and the text is used to highlight the structures they are related to. The same color-coding is extended to the diagrams summarizing bidirectional killing and experimental results showing BsAb efficacy, to help relate the diagrams to the main image. Diagrams are kept minimalistic with key colors to help focus the viewer on the didactic content of the diagrams.
